RPG Life Sciences Buys Raghava’s API Business For ₹135 Crore

RPG Life Sciences has strengthened its pharmaceutical manufacturing business by acquiring the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences for ₹135 crore.

The acquisition was made through RPG Life Sciences' wholly-owned subsidiary, RPG Active Pharma Ltd, which has entered into a business transfer agreement with Raghava Life Sciences. The transaction will be completed as a going concern through a slump sale and is subject to customary closing conditions and necessary regulatory approvals.

The acquisition will add 22 commercialised APIs and seven development-stage assets to RPG Active Pharma's portfolio, spanning therapeutic areas including diabetes, cardiovascular diseases, and central nervous system disorders. This marks RPG Active Pharma's second strategic acquisition, following the acquisition of Actis Generics, and is aimed at expanding the company's integrated API capabilities and manufacturing footprint.

According to RPG Life Sciences Managing Director Ashok Nair, the acquisition is an important addition to the company's consolidated organization and will help build a larger presence in the growing API market. The company intends to combine the manufacturing and product capabilities of Raghava Life Sciences with the intermediate strengths of Actis Generics to capture a greater share of the API market.

The ₹135-crore transaction will be financed through a recent equity raise undertaken by RPG Active Pharma. Quillon Partners acted as legal adviser for the acquisition, while o3 Capital and Deloitte served as financial and due diligence partners, respectively.

The acquisition strengthens RPG Life Sciences' API business as the company seeks greater scale across pharmaceutical ingredients and intermediates. With this acquisition, RPG Life Sciences is poised to expand its presence in the pharmaceutical manufacturing business and increase its market share in the API segment.

RPG Life Sciences is a leading pharmaceutical company in India, and this acquisition is a strategic move to strengthen its position in the market. The company's focus on expanding its API capabilities and manufacturing footprint is expected to drive growth and increase its competitiveness in the industry.

In recent times, the Indian pharmaceutical industry has seen significant growth, driven by increasing demand for high-quality APIs and intermediates. The acquisition of Raghava Life Sciences' API business is a timely move by RPG Life Sciences to capitalize on this trend and establish itself as a major player in the API market.

Overall, the acquisition of Raghava Life Sciences' API business is a significant development for RPG Life Sciences, and is expected to have a positive impact on the company's growth and profitability in the coming years.

The deal is also expected to benefit the pharmaceutical industry as a whole, as it will lead to increased competition and innovation in the API segment. With RPG Life Sciences' expanded capabilities and increased market share, the company is well-positioned to meet the growing demand for high-quality APIs and intermediates in the industry.

In conclusion, the acquisition of Raghava Life Sciences' API business by RPG Life Sciences is a strategic move that is expected to drive growth and increase the company's competitiveness in the pharmaceutical manufacturing business. The deal is a significant development for the Indian pharmaceutical industry, and is expected to have a positive impact on the industry as a whole.

The acquisition is a testament to RPG Life Sciences' commitment to expanding its presence in the pharmaceutical manufacturing business and increasing its market share in the API segment. With this deal, the company is poised to establish itself as a major player in the API market and drive growth and innovation in the industry.

The Indian pharmaceutical industry is expected to continue growing in the coming years, driven by increasing demand for high-quality APIs and intermediates. RPG Life Sciences is well-positioned to capitalize on this trend, with its expanded capabilities and increased market share. The company's focus on expanding its API capabilities and manufacturing footprint is expected to drive growth and increase its competitiveness in the industry.

In the long term, the acquisition of Raghava Life Sciences' API business is expected to have a positive impact on RPG Life Sciences' growth and profitability. The company's increased market share and expanded capabilities are expected to drive growth and innovation in the industry, and establish RPG Life Sciences as a major player in the API market.

The deal is also expected to benefit the company's stakeholders, including its shareholders and employees. The acquisition is a significant development for the company, and is expected to lead to increased growth and profitability in the coming years.

In terms of the company's financials, the acquisition is expected to have a positive impact on RPG Life Sciences' revenue and profitability. The company's increased market share and expanded capabilities are expected to drive growth and increase its competitiveness in the industry.

Overall, the acquisition of Raghava Life Sciences' API business by RPG Life Sciences is a strategic move that is expected to drive growth and increase the company's competitiveness in the pharmaceutical manufacturing business. The deal is a significant development for the Indian pharmaceutical industry, and is expected to have a positive impact on the industry as a whole.

The acquisition marks an important milestone for RPG Life Sciences, as the company continues to expand its presence in the pharmaceutical manufacturing business. With this deal, the company is poised to establish itself as a major player in the API market and drive growth and innovation in the industry.

In conclusion, the acquisition of Raghava Life Sciences' API business by RPG Life Sciences is a significant development for the company and the Indian pharmaceutical industry. The deal is expected to have a positive impact on the company's growth and profitability, and is a testament to RPG Life Sciences' commitment to expanding its presence in the pharmaceutical manufacturing business.

What it means for Mumbai and India is that the acquisition will lead to increased competition and innovation in the API segment, which will benefit the pharmaceutical industry as a whole. The deal is also expected to drive growth and increase RPG Life Sciences' competitiveness in the industry, which will have a positive impact on the company's stakeholders, including its shareholders and employees.

The acquisition is a significant development for the Indian pharmaceutical industry, and is expected to have a positive impact on the industry's growth and innovation. With RPG Life Sciences' expanded capabilities and increased market share, the company is well-positioned to meet the growing demand for high-quality APIs and intermediates in the industry.

In the coming years, the Indian pharmaceutical industry is expected to continue growing, driven by increasing demand for high-quality APIs and intermediates. RPG Life Sciences is poised to capitalize on this trend, with its expanded capabilities and increased market share. The company's focus on expanding its API capabilities and manufacturing footprint is expected to drive growth and increase its competitiveness in the industry.

Overall, the acquisition of Raghava Life Sciences' API business by RPG Life Sciences is a strategic move that is expected to drive growth and increase the company's competitiveness in the pharmaceutical manufacturing business. The deal is a significant development for the Indian pharmaceutical industry, and is expected to have a positive impact on the industry as a whole.